Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Shattuck Labs, Inc. (STTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights –Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer at the American Society of Clinical Oncology 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort –"
05/31/2023 4 Redmile Group, LLC (10% Owner) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Lee Michael Stewart (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Boudreau Helen M (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Golumbeski George (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Gibson Neil W (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Brownstein Carrie (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/31/2023 4 Brous Tyler (Director) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 40,258 options to buy @ $2.72, valued at $109.5k
05/24/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights –Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting in June –"
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 3 Stout Stephen (See Remarks) has filed a Form 3 on Shattuck Labs, Inc.
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates –Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –"
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in SHATTUCK LABS INC
01/27/2023 4 Neill Andrew R (CFO) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 34,925 shares @ $0
Granted 69,850 options to buy @ $3.57, valued at $249.4k
01/27/2023 4 Thomson Erin Ator (General Counsel) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 24,125 shares @ $0
Granted 48,250 options to buy @ $3.57, valued at $172.3k
01/27/2023 4 Shukla Abhinav A. (Chief Technical Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 26,100 shares @ $0
Granted 52,200 options to buy @ $3.57, valued at $186.4k
01/27/2023 4 Pandite Arundathy N. (Chief Medical Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 37,875 shares @ $0
Granted 69,750 options to buy @ $3.57, valued at $249k
01/27/2023 4 DeYoung Casi (Chief Business Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 27,100 shares @ $0
Granted 54,200 options to buy @ $3.57, valued at $193.5k
01/27/2023 4 Schreiber Taylor (CEO) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Granted 165,050 options to buy @ $3.57, valued at $589.2k
01/12/2023 4 DeYoung Casi (Chief Business Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Paid exercise price by delivering 1,583 shares @ $3.03, valued at $4.8k
01/12/2023 4 Pandite Arundathy N. (Chief Medical Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Paid exercise price by delivering 2,987 shares @ $3.03, valued at $9.1k
01/12/2023 4 Shukla Abhinav A. (Chief Technical Officer) has filed a Form 4 on Shattuck Labs, Inc.
Txns: Paid exercise price by delivering 1,933 shares @ $3.03, valued at $5.9k
12/08/2022 SC 13D/A Hornblower Josiah reports a 7% stake in SHATTUCK LABS, INC.
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights –Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer&#59; complete data expected midyear 2023 –"
08/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy